Table 1.
Regimen | Study | N | Genotype | Cirrhosis (%) | SVR12 | Author (ref) |
---|---|---|---|---|---|---|
SOFOSBUVIR+RIBAVIRIN 24 weeks |
Prospective Multicenter Open-label |
40 | All (83% G1) | Yes (40%) | 70% | Charlton, M. 65 |
SOFOSBUVIR+DACLATASVIR+RIBAVIRIN 12 weeks (ALLY-1) |
Prospective Multicenter Open-label |
53 | All (77% G1) | Yes | 94% | Poordad, F. 39 |
SOFOSBUVIR+DACLATASVIR±RIBAVIRIN 12 or 24 weeks (ANRS CO23 CUPILT) |
Prospective Multicenter Real-life cohort |
130 | All (82% G1) | Yes (31%) | 96% | Coilly, A. 70 |
PARITAPREVIR+OMBITASVIR/r+DASABUVIR+ RIBAVIRIN 24 weeks |
Prospective Multicenter Open-label |
34 | Only G1 | No | 97% | Kwo, PY. 74 |
SOFOSBUVIR+LEDIPASVIR+RIBAVIRIN 12 or 24 weeks (SOLAR I and II) |
Prospective randomized phase II study | 444 | G1 (>95%) and G4 | Yes (about 50%) | 92% | Charlton, M. 37 Manns, M. 38 |
SOFOSBUVIR+SIMEPREVIR±RIBAVIRIN 12 weeks |
Prospective Multicenter Open-label |
109 | Only G1 | F3–F4 (29%) | 90% | Pungpapong, S. 143 |
SOFOSBUVIR+SIMEPREVIR±RIBAVIRIN 12 weeks (HCV-TARGET) |
Prospective Multicenter Real-life cohort |
143 | All (80% G1) | Yes (56%) | 90% (SVR4) | Sulkowski, M. 144 |